HK Experts Divided Over AstraZeneca Order

"); jQuery("#212 h3").html("

Related News Programmes

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1584710_1_20210408175336.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1584710-20210408.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1584710-20210408.htm', 'DCS.dcsqry', '' ); } } }); }); });

2021-04-08 HKT 10:59

Share this story

facebook

  • While experts are divided on whether Hong Kong should still purchase AstraZeneca jabs, they agree that the city should consider buying other vaccines. Photo: AFP

    While experts are divided on whether Hong Kong should still purchase AstraZeneca jabs, they agree that the city should consider buying other vaccines. Photo: AFP

Medical experts in Hong Kong are divided on whether the government should go ahead with its order for 7.5 million doses of the AstraZeneca vaccine, following the latest findings linking the jab to rare blood clots

The European Medicines Agency announced that unusual blood clots should be listed as a very rare, possible side-effect of the AstraZeneca jab, adding that its benefits still outweigh the risks.

The regulator had not been able to identify pre-existing risk factors in clotting cases, although most victims were women under the age of 60.

Speaking on an RTHK radio show on Thursday, William Chui from the Society of Hospital Pharmacists explained that this might be linked to the widespread use of oral contraceptives among young women in Europe, as birth control pills can also cause blood clots.

Though AstraZeneca has yet to apply for emergency use in Hong Kong, Chui said the government should only purchase, at most, half of the original order of 7.5 million doses.

While officials might be contractually obliged to buy a certain amount, he said it would be wasteful to go ahead with the original order as Hong Kong people might be reluctant to get this jab.

The expert urged the government to consider alternatives – like the Johnson & Johnson jab – to diversify risks and increase public confidence in vaccines.

David Hui from the Chinese University also told RTHK that the Johnson & Johnson vaccine is a good choice, adding that officials can also consider waiting for second-generation shots.

He said according to his understanding, the SAR government has only entered into an initial agreement with AstraZeneca, which means it is still possible to scrap the order altogether.

Hui's comment was echoed by University of Hong Kong microbiologist Ho Pak-leung, who also urged the government to cancel the AstraZeneca order, saying there's no evidence to show that it is any better than the two vaccines currently on offer in the territory.

But unlike Chui and Hui, Ho cautioned against purchasing viral vector-based vaccines, such as the Johnson & Johnson jab.

He warned that like AstraZeneca, problems such as rare blood blots could also emerge from the use of the Johnson & Johnson vaccine.

RECENT NEWS

StartmeupHK Festival And Hong Kong Fintech Week 2025 Merge For 10th Anniversary Milestone

Invest Hong Kong (InvestHK) announced on 10 March 2025 that both of its flagship events, Hong Kong Fintech Week 2025 an... Read more

Ant AI-Powered Health Insurance Processes 7.25M Claims In 2024, 55%YoY Increase

In 2024, Ant Insurance, the online insurance brokerage platform of Ant Group, processed 7.25 million health claims, mar... Read more

Ping An Talent Uses AI For Job Matching, But Can Technology Make Recruitment Fairer?

Ping An Insurance (Group) Company of China, Ltd. has launched its 2025 Spring Campus Recruitment, offering over 2,000 p... Read more

HKEX Partners With CMU OmniClear To Boost Post-Trade Securities Infrastructure

Hong Kong Exchanges and Clearing Limited (HKEX) announced on 4 March 2025 that it signed a Memorandum of Understanding ... Read more

PAObank Secures Insurance Agency Licence, Partners With Ping An And FWD Hong Kong

PAO Bank Limited (PAObank) has received its Insurance Agency Licence from the Insurance Authority and signed strategic ... Read more

IFAST Launches Self-Service Accounts For Hong Kong Family Offices

Fintech solutions provider iFAST HK launches self-service accounts in Hong Kong, catering to the growing demand for ind... Read more